{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:42:08Z","timestamp":1790156528580,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nitric Oxide"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.niox.2012.12.001","type":"journal-article","created":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T10:17:18Z","timestamp":1355221038000},"page":"17-24","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Sara","family":"Huerta-Yepez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Baritaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermina","family":"Baay-Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Hernandez-Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles","family":"Hernandez-Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario I.","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonavida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.niox.2012.12.001_b0005","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ejca.2010.03.019","article-title":"Anti-cancer drug resistance. understanding the mechanisms through the use of integrative genomics and fucntional RNA interference","volume":"46","author":"Tan","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.niox.2012.12.001_b0010","first-page":"151","article-title":"Notch: a key regulator of tumor angiogenesis and metastasis","volume":"27","author":"Garcia","year":"2012","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.niox.2012.12.001_b0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.niox.2012.12.001_b0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdl963","article-title":"Apoptosis: a relevant tool for anticancer therapy","volume":"17","author":"Russo","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.niox.2012.12.001_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2007.01.002","article-title":"Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent","volume":"10","author":"Katsman","year":"2007","journal-title":"Drug Resist. Updat."},{"issue":"2","key":"10.1016\/j.niox.2012.12.001_b0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.niox.2008.04.018","article-title":"Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases","volume":"19","author":"Bonavida","year":"2008","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.niox.2012.12.001_b0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.niox.2008.08.001","article-title":"Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1","volume":"20","author":"Huerta-Yepez","year":"2009","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.niox.2012.12.001_b0040","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1038\/sj.onc.1207655","article-title":"Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression","volume":"23","author":"Huerta-Yepez","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.niox.2012.12.001_b0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/niox.1996.0108","article-title":"Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin","volume":"1","author":"Wink","year":"1997","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.niox.2012.12.001_b0050","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-09-1234","article-title":"Rituximab-mediated cell signaling and chemo\/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions","volume":"15","author":"Vega","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.niox.2012.12.001_b0055","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.4049\/jimmunol.179.8.5441","article-title":"Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation","volume":"179","author":"Baritaki","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.niox.2012.12.001_b0060","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.niox.2008.11.006","article-title":"In vitro and in vivo sensitication of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: involvement of AIP","volume":"20","author":"Huerta","year":"2009","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.niox.2012.12.001_b0065","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.1249","article-title":"A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats","volume":"50","author":"Zhang","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.niox.2012.12.001_b0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.juro.2009.10.046","article-title":"An update of the Gleason grading system","volume":"183","author":"Epstein","year":"2010","journal-title":"J. Urol."},{"key":"10.1016\/j.niox.2012.12.001_b0075","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1158\/1078-0432.CCR-07-0960","article-title":"Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence","volume":"13","author":"Seligson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.niox.2012.12.001_b0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/infdis\/137.2.122","article-title":"A method for testing for synergy with any number of agents","volume":"137","author":"Berenbaum","year":"1978","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.niox.2012.12.001_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.niox.2010.10.001","article-title":"Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-kappaB\/Snail\/YY1\/RKIP circuitry","volume":"24","author":"Bonavida","year":"2011","journal-title":"Nitric Oxide"},{"issue":"2","key":"10.1016\/j.niox.2012.12.001_b0090","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.niox.2008.04.018","article-title":"Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases","volume":"19","author":"Bonavida","year":"2008","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.niox.2012.12.001_b0100","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-06-1807","article-title":"Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling","volume":"13","author":"Frederiksen","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.niox.2012.12.001_b0110","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2174\/138161208784246225","article-title":"Chemosensitization of cancer by nitric oxide","volume":"14","author":"Sullivan","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.niox.2012.12.001_b0115","first-page":"131","article-title":"Expression of transcription factor Yin Yang 1 in prostate cancer","volume":"27","author":"Seligson","year":"2005","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.niox.2012.12.001_b0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/pros.20723","article-title":"Androgen receptor-dependent regulation of Bcl-xL expression: implication in prostate cancer progression","volume":"68","author":"Sun","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.niox.2012.12.001_b0125","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4049\/jimmunol.175.4.2174","article-title":"Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin\u2019s lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively","volume":"175","author":"Vega","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.niox.2012.12.001_b0130","doi-asserted-by":"crossref","first-page":"8841","DOI":"10.1073\/pnas.0403034101","article-title":"S-nitrosylation: physiological regulation of NF-kappaB","volume":"101","author":"Marshall","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.niox.2012.12.001_b0135","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1471-4159.2008.05661.x","article-title":"Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma","volume":"107","author":"Gabellini","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.niox.2012.12.001_b0140","first-page":"6052","article-title":"Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity","volume":"60","author":"Lebedeva","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.niox.2012.12.001_b0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-5347(05)65964-2","article-title":"Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides","volume":"166","author":"Lebedeva","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.niox.2012.12.001_b0150","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.4161\/cc.10.16.16952","article-title":"Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis","volume":"10","author":"Martinez-Paniagua","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.niox.2012.12.001_b0155","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1535-7163.MCT-08-0333","article-title":"Natural BH3 mimetic (\u2212)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa","volume":"7","author":"Meng","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.niox.2012.12.001_b0160","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/JTO.0b013e31822e2941","article-title":"A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer","volume":"6","author":"Baggstrom","year":"2011","journal-title":"J. Thorac. Oncol."}],"container-title":["Nitric Oxide"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089860312004053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089860312004053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T22:42:14Z","timestamp":1562452934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089860312004053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":30,"alternative-id":["S1089860312004053"],"URL":"https:\/\/doi.org\/10.1016\/j.niox.2012.12.001","relation":{},"ISSN":["1089-8603"],"issn-type":[{"value":"1089-8603","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}